Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma
This is an open-label, prospective, multicentre, phase IIa study, evaluating a new
therapeutic agent in the management of patients suffering from inoperable or non resectable
biliary carcinoma. The patients will receive the dose of WST11 according to order of
inclusion. The first 3 patients will receive 2.5 mg/kg. In the absence of toxicity, the
following 9 patients will receive the dose of 5 mg/kg.
The patient is to receive anesthesia. WST11-mediated therapy will consist of the
combination of single IV administration of WST11 at doses of 2.5mg/kg or 5mg/kg, using 753nm
laser light at a fixed power of (150mW/cm) and light energy (200 J/cm) delivered through a
diffusing fiber. The fiber is introduced in a transparent standard ERCP catheter and
positioned under radioscopy in front of the lesion.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of the safety based on analysis of adverse events (clinical laboratory tests, electrocardiogram, physical examination, absence of local or general complications and phototoxicity) of WST11 in inoperable or non resectable cholangiocarcinoma
Patient inclusion - Month 6
Yes
Emmanuel Ben Soussan, MD
Principal Investigator
Clinique de l'Alma
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
CLIN904 CCM201
NCT00975039
September 2009
September 2012
Name | Location |
---|